Table 5.
Outcome measure (possible range of scores) | Baseline | Post-intervention |
Baseline to
post intervention (n = 5) |
Follow-up |
Baseline to
follow-up (n = 4)‡ |
||||
---|---|---|---|---|---|---|---|---|---|
Mdn (IQR) | Mdn (IQR) | z | p | r (ES) | Mdn (IQR) | z | p | r (ES) | |
SIS domains (0–100) | |||||||||
Strength | 50.00 (28.50–75.00) | 50.0 (34.50–78.50) | −0.0680 | 0.496 | −0.030 | 47.00 (38.75–87.50) | −0.535 | 0.593 | −0.268 |
Memory and thinking | 68.00 (43.00–89.50) | 89.00 (68.00–93.00) | −1.841† | 0.066 | −0.823 | 82.00 (52.25–98.25) | −1.826† | 0.068 | −0.913 |
Emotion | 81.00 (54.50–94.00) | 86.00 (71.00–90.00) | −0.535 | 0.593 | −0.239 | 79.00 (63.75–94.25) | 0.000 | 1.000 | 0.000 |
Communication | 89.00 (73.50–96.50) | 96.00 (89.00–98.00) | −1.826† | 0.068 | −0.817 | 80.00 (64.75–98.25) | −0.365 | 0.715 | −0.183 |
ADL/IADL | 80.00 (41.50–90.50) | 75.0 (52.50–93.00) | −0.813 | 0.416 | −0.364 | 70.0 (51.75–90.50) | −1.095 | 0.273 | −0.548 |
Mobility | 64.00 (44.50–86.00) | 75.00 (69.50–86.00) | −1.289 | 0.197 | −0.577 | 72.00 (61.75–90.50) | −0.736 | 0.461 | −0.368 |
Hand function | 50.00 (15.00–85.00) | 70.00 (30.00–90.00) | −1.490 | 0.136 | −0.666 | 55.00 (21.25–85.00) | −0.184 | 0.854 | −0.092 |
Participation | 69.00 (31.00–94.00) | 84.00 (34.50–97.00) | −1.095 | 0.273 | −0.490 | 56.00 (53.00–85.25) | −1.089 | 0.276 | −0.545 |
General recovery | 65.00 (45.00–85.00) | 70.00 (45.00–82.50) | 0.000 | 1.000 | 0.000 | 60.00 (27.50–92.50) | −0.365 | 0.715 | −0.183 |
SIS, the stoke impact scale, higher scores reflect better QoL (82); QoL, quality of life; Mdn, Median; IQR, interquartile range; EF, effect size.
An effect size (r) was calculated from the z value of Wilcoxon signed-rank test () (94) and can be interpreted as a small (r ≤ 0.10), medium (r = 0.30), and large (r ≥ 0.50) effect size (95).
near statistical significance; 0.05 ≤ p < 0.1.
Participant 4 was lost to follow-up due to an unstable medical condition unrelated to the study intervention, and he was therefore not included in the baseline to follow-up analysis.